, Volume 45, Supplement 1, pp S5–S12 | Cite as

Revealing the cost of Type II diabetes in Europe




‘The Cost of Diabetes in Europe-Type II study’ is the first coordinated attempt to measure total healthcare costs of Type II (non-insulin-dependent) diabetes mellitus in Europe. The study evaluated more than 7000 patients with Type II diabetes in eight countries — Belgium, France, Germany, Italy, the Netherlands, Spain, Sweden and the United Kingdom.


A bottom-up, prevalence-based design was used, which optimised the collection of data at the national level while maintaining maximum international comparability. Effort was made to ensure consistency in terms of data specification, data collection tools and methods, sampling design, and the analysis and reporting of results. Results are reported for individual countries and in aggregate for the total study population.


The total direct medical costs of Type II diabetes in the eight European countries was estimated at EUR 29 billion a year (1999 values). The estimated average yearly cost per patient was EUR 2834 a year. Of these costs, hospitalisations accounted for the greatest proportion (55%, range 30-65%) totalling EUR 15.9 billion for the eight countries. During the 6-month evaluation period, 13% of the Type II diabetic patients were hospitalised, with an average of 23 days in hospital projected annually. In contrast, drug costs for managing Type II diabetes were relatively low, with antidiabetic drugs and insulin accounting for only 7% of the total healthcare costs for Type II diabetes.


Type II diabetes mellitus is a common disease and the prevalence is expected to increase considerably in the future, especially in developing countries. Current comprehensive economic data on the costs of diabetes are required for policy decisions to optimise resource allocation and to evaluate different approaches for disease management.

Type II diabetes pharmacoeconomics Europe 



Cost of diabetes in Europe — Type II


diagnosis-related group


general practitioner


health-related quality of life


international classification of diseases


intensive care unit


organization for economic co-operation and development


  1. 1.
    McCarty D, Zimmet P (1994) Diabetes 1994 to 2010: global estimates and projections. International Diabetes Institute, MelbourneGoogle Scholar
  2. 2.
    Amos AF, McCarty D, Zimmet P (1997) The rising global burden of diabetes and its complications: estimates and projections to the year 2010. Diabet Med 14 [Suppl 5]: S7–S85CrossRefGoogle Scholar
  3. 3.
    King H, Aubert RE, Herman WH (1998) Global burden of diabetes, 1995-2025: prevelance, numerical estimates, and projections. Diabetes Care 21:1414–1431Google Scholar
  4. 4.
    Ray N, Willis S, Thamer M (1993) Direct and indirect costs of diabetes in the United States in 1992. American Diabetes Association, AlexandriaGoogle Scholar
  5. 5.
    Harris MI, Flegal KM, Cowie CC et al. (1998) Prevalence of diabetes, impaired fasting glucose, and impaired glucose tolerance in U.S. adults. The Third National Health and Nutrition Examination Survey, 1988-1994. Diabetes Care 21:518–524Google Scholar
  6. 6.
    United Kingdom Prospective Diabetes Study (UKPDS) Group (1998) Intensive blood-glucose control with sulpho-nylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 352:837–853CrossRefGoogle Scholar
  7. 7.
    Simanis JG (1987) Health care expenditures: international comparisons, 1970-80. Soc Secur Bull 50:19–24PubMedGoogle Scholar
  8. 8.
    Organization for Economic Cooperation and Development (1990) Health care systems in transition; the search for efficiency. Organization for Economic Cooperation and Development (OECD) Social Policy Studies No. 7. Paris pp 129–135Google Scholar
  9. 9.
    Laing W, Williams R (1989) Diabetes: a model for health care management. Office of Health Economics, LondonGoogle Scholar
  10. 10.
    American Diabetes Association (1998) Economic consequences of diabetes in the U.S. in 1997. Diabetes Care 21:296–309CrossRefGoogle Scholar
  11. 11.
    Brown JB, Pedula KL, Bakst AW (1999) The progressive cost of complications in type 2 diabetes mellitus. Arch Intern Med 159:1873–1880CrossRefPubMedGoogle Scholar
  12. 12.
    Rubin RJ, Altman WM, Mendelson DN (1994) Health care expenditures for people with diabetes mellitus. J Endocrinal Metab 78:809A–809ACrossRefGoogle Scholar
  13. 13.
    Jönsson B (1983) Diabetes — the cost of illness and the cost of control. Acta Med Scand 671 [Suppl]: 19–27Google Scholar
  14. 14.
    Henriksson F, Jönsson B (1998) Diabetes: the cost of illness in Sweden. J Internal Med 244:461–468CrossRefPubMedGoogle Scholar
  15. 15.
    Marks L (1996) Counting the Cost — The real impact of non-insulin dependent diabetes. Kings Fund Report com-missioned by the British Diabetic Association, LondonGoogle Scholar
  16. 16.
    Laing W, Williams R (1989) Diabetes: a model for health care management. No 92 in a series of papers on current health problems. Office of Health Economics, LondonGoogle Scholar
  17. 17.
    Koopmanschap M (2002) Coping with Type 2 diabetes: the patient perspective. Diabetologia supplement (this issue)Google Scholar
  18. 18.
    Detournay B, Vauzelle-Kervroedan F, Charles MA et al. (1999) Epidemiology, management and costs of Type 2 di abetes in France, in 1998. Diabetes Metab 25:356–365PubMedGoogle Scholar
  19. 19.
    Williams R, Van Gaa L, Lucioni C (2002) Assessing the impact of complications on the costs of Type 2 diabetes. Diabetologia supplement (this issue)Google Scholar
  20. 20.
    Gesundheitsbericht für Deutschland (1998) Statistisches Bundesamt, Gesundheitsberichterstattung des Bundes, Metzler-Poeshel, StuttgartGoogle Scholar
  21. 21.
    Vaccaro O, Bonora E, Bruno G, Garancini MP, Muntoni S (1996) L’epidemiologia del diabete non-insulino-dipendente e delia ridotta tolleranza al glucosio II diabete in Italia. Kurds Milano, pp 17–30Google Scholar
  22. 22.
    Baan CA, Bonneux L, Ruwaard D, Feskens EJM (1998) The prevalence of diabetes mellitus in the Netherlands. A quantitative review. Eur J Public Health:210–216Google Scholar
  23. 23.
    The Regional Autonomous Government of Catalunya (1997) Prevalenca de diabetis mellitus no insulinodependent a Catalunya. Bulleti Epidemiologic de Catalunya. Conseil Asesor sobre la Diabetis e Catalunya Vol 18, No. 3, Department de Sanitat i Seguretat Social CatalunyaGoogle Scholar
  24. 24.
    Berger B, Stenstrom G, Sundkvist G (1999) Incidence, prevalence, and mortality of diabetes in a large population. Diabetes Care 22:773–777CrossRefPubMedGoogle Scholar
  25. 25.
    Organization for Economic Cooperation and Development (2000) OECD Health data 00 CD ROM. Organization for Economic Cooperation and Development, ParisGoogle Scholar

Copyright information

© Springer-Verlag 2002

Authors and Affiliations

  1. 1.Centre for Health EconomicsStockholm School of EconomicsStockholmSweden

Personalised recommendations